Dose ratio between morphine and hydromorphone in patients with cancer pain: A retrospective study

Pain

Volumn 72, Issue 1-2, 1997, Pages 79-85

  Lawlor, P ^a   Turner, K ^a   Hanson, J ^a   Bruera, E ^a  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

Cancer pain; Dose ratio; Equianalgesic tables; Hydromorphone; Morphine; Opioid rotation

Indexed keywords

HYDROMORPHONE; METHADONE; MORPHINE;

ANALGESIC ACTIVITY; ARTICLE; CANCER PAIN; CANCER PALLIATIVE THERAPY; DOSE RESPONSE; DRUG TOLERANCE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030860177     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(97)00018-3     Document Type: Article

References (27)

1. Babul, N. and Darke, A.C., Putative role of hydromorphone metabolites in myoclonus, Pain, 51(2) (1992) 260–261.
2. Bruera, E. and Lawlor, P., Cancer pain management, Acta Anaesthesiol. Scand., 41(Suppl.) (1997) 1–8.
3. Bruera, E., Pereira, J., Watanabe, S., Belzile, M., Kuehn, N. and Hanson, J., Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine, Cancer, 78(4) (1996) 852–857.
4. Bruera, E., Franco, J.J., Maltoni, M., et al., Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration and opiate rotation, J. Pain Symptom Manag., 10(4) (1995) 287–291.
5. Bruera, E. and Ripamonti, C., Alternate routes of administration of opioids for the management of cancer pain. In: R. Patt (Ed.), Cancer Pain, JB Lippincott Co., Philadelphia, PA, 1993, pp. 161–184.
6. Management of Cancer Pain. Clinical Practice Guidelines, U.S. Department of Health and Human Services, AHCPR Publications, Rockville, MD., No. 94-0592, March 1994.
7. Cherny, N.I. and Foley, K.M., Non-opioid and opioid analgesic pharmacotherapy of cancer pain. In: N.I. Cherny and K.M. Foley (Eds.), Hematol. Oncol. Clin. of North Am., Vol 10, No. 1, (1996) 79–101.
8. de Stoutz, N.D., Bruera, E. and Suarez-Almazor, M., Opioid rotation (OR) for toxicity reduction in terminal cancer patients, J. Pain Symptom Manage., 10(5) (1995) 378–384.
9. Eisele, J.H. Jr, Griesby, E.J. and Gilland, D., Clonazepam treatment of myoclonic contgrctions associated with high dose opioids: case report, Pain, 49 (1992) 231–232.
10. Foley, K., The treatment of cancer pain, N. Engl. J. Med. 313 (1985) 84–95.
11. Folstein, M.F., Folstein, S. and McHugh, P.R., `Mini-mental state': a practical method for grading the cognitive state of patients for the clinician, J. Psychiatr. Res., 12 (1975) 189–198.
12. Cancer pain: a monograph on the management of cancer pain. Health and Welfare Canada: Minister of Supply and Services Canada, Ottawa H42–2/5, 1984E.
13. Houde, R.W., Clinical analgesic studies of hydromorphone. In: K.M. Foley and C.E. Inturrisi (Eds.), Opioid Analgesics in the Management of Clinical Pain. Advances in Pain Research and Therapy, Vol 8, New York: Academic Press, 1986, pp. 129–136.
14. Houde, R.W., Wallenstein, S.L. and Beaver, W.T., Evaluation of analgesics in patients with cancer pain. In: L. Lasagna, (Ed.), International Encyclopedia of Pharmacology and Therapeutics. Section 6. Clinical Pharmacology, Vol 1, New York: Pergamon Press, 1966, 59–97.
15. Inturrisi, C.E. and Hanks, G., Opioid analgesic therapy. In: D. Doyle, G.W.C. Hanks, N. MacDonald (Eds.), Oxford Textbook of Palliative Care, Vol. 4.2.3, Oxford: Oxford University Press, 1993, pp. 166–181.
16. MacDonald, N., Der, L., Allan, S. et al., Opioid hyperexcitability: the application of alternate opioid therapy, Pain, 53 (1993) 353–355.
17. Mahler, D.L. and Forrest, W.H. Jr., Relative analgesic potencies of morphine and hydromorphone in postoperative pain, Anaesthesiology, 42(5) (1975) 602–607.
18. Morley, J., Miles, J.B., Wells, J.C. and Bowsher, D., Paradoxical pain, Lancet, 340 (1992) 1045.
19. Portenoy, R.K., Foley, K.M. and Inturrisi, C.E., The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions, Pain, 43 (1990) 273–286.
20. Robinson, K. and Bruera, E., Case report: The management of pain in patients with advanced cancer: the importance of multidimensional assessments, J. Palliat. Care, 11(4) (1995) 51–53.
21. Sawe, J., Dahlstrom, B., Paalzow, L., et al., Morphine kinetics in cancer patients, Clin. Pharmacol. Ther., 30 (1981) 629–635.
22. Shott, S. (Ed), Statistics for health professionals, W.B. Saunders Company, Philadelphia, 1990, pp. 125–127.
23. Sjogren, P., Jensen, N-H. and Jensen, T.S., Disappearance of morphine induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists, Pain (1994) 313–316.
24. Small, L.Y., Eddy, N.B., Mosetting, E. and Himmelsbach, C.K., Studies on drug addiciton: with special reference to chemical structures of opium derivatives and allied synthetic substances and their physiological actions, Public Health Report (Suppl 138), US Govt. Printing Office, Washington, DC, 1938, pp. 1–143.
25. Smith, M.J., Watt, J.A. and Cramond, T., Morphine-3-glucuronide – a potent antagonist of morphine analgesia, Life Sci., 47 (1990) 579–585.
26. Watanabe, S., Belzile, M., Kuehn, N., Hanson, J. and Bruera, E. (abstract) Capsules and suppositories of methadone for patients on high dose opioids for cancer pain: clinical and economic considerations. Presented at the Royal College of Physicians and Surgeons of Canada and the Canadian Association of Medical Oncologists/Canadian Oncology Society Symposium Symptom Control in the Elderly Patients with Cancer, Montreal, PQ, Sept. 15–16, 1995.
27. World Health Organization Expert Committee Report 1990, Cancer pain relief and palliative care. Technical Series 804, Geneva, Switzerland: World Health Organization.